Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
2019年12月4日 - 10:00PM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that it has received a Notice of Allowance from the United
States Patent and Trademark Office (USPTO) for Seelos' U.S. Patent
number 10,493,023 (Application number 14/889,727) titled:
“TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE
DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE” (SLS-005).
There are several neurodegenerative conditions related by the
commonality of protein aggregations including Sanfilippo syndrome,
Oculopharyngeal Muscular Dystrophy (OPMD), Spinocerebellar Ataxia
(SCA3), Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS),
Alzheimer’s Disease, Huntington's disease and Friedreich Ataxia
(FA). The USPTO granted Seelos a patent for treating FA with
trehalose in July 2019.
Seelos was previously granted orphan indication from the United
States Food and Drug Administration for SCA3 and OPMD for trehalose
as well as Fast Track designation for OPMD.
About Trehalose
Trehalose is a low molecular weight disaccharide (.342 kDa) that
crosses the blood brain barrier, stabilizes proteins, and
importantly activates autophagy which is the process that clears
material from cells. In several animal models of diseases,
associated with abnormal cellular protein aggregation or storage of
pathologic material, it has been shown to reduce aggregation of
misfolded proteins and reduce accumulation of pathologic material.
Trehalose activates autophagy through the activation of
Transcription Factor EB (TFEB), a key factor in lysosomal and
autophagy gene expression. Activation of TFEB is an emerging
therapeutic target for a number of diseases with pathologic
accumulation of storage material.
Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024